Neuropathy in metabolic syndrome and non-diabetic dysglycemia
DOI:
https://doi.org/10.47196/diab.v49i2.202Keywords:
diabetic neuropathy, metabolic syndrome, non-diabetic disglycemiaAbstract
Diabetic neuropathy (DN) is the most common and early microvascular alteration associated to diabetes mellitus (DM); however, this event is most missed and less diagnosed. At the same time, it is widely known that metabolic syndrome (MS) is highly prevalent and the relationship between this status and macrovascular commitment is documented. The Diabetic Neuropathy Committee is focused in analyzing the neuropathic effect within the framework of MS and in one of its components such as non-diabetic disglycemia. The under diagnosis and increase of morbidity and mortality risk of these patients alert the medical community of the existence of this microvascular alteration exceeding the DM framework and is also present in MS and disglycemia either at fasting and postprandial.
References
Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity. National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2011; 34:1642-1647.
Eckel EH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
Gordon Smith A, Kristi Rose J, Singleton R. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J. Neurol. Sci. 2008; October 15; 273(1-2): 25-28.
Bongaerts BWC, Rathmann W, Heier M, et al. Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy. The KORA F4 Study. Diabetes Care 2013; 36: 1141-1146.
Gordon Smith, A. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy REVIEW. Journal of the Peripheral Nervous System 2012; 17 (Supplement):15-21.
Fuente G, Urdaneta Velez R, Lifszyc P. Neuropatía autonómica cardíaca en pacientes con síndrome metabólico. Pren. Med. Argent. 2011; 98: 469-475.
Vinik AI, Nevoret ML. Neuropathy in prediabetes and metabolic. In syndrome prevention of type 2 diabetes; from science to therapies (Cap. 8). Editor Derek LeRoith Department of Medicine Mount Sinai School of Medicine New York, USA. Springer Science Business Media, New York, 2012.
Bongaerts BWC, Rathmann W, Kowall B, et al. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy. The KORA F4 Study. Diabetes Care 2012; 35: 1891-1893.
Ziegler D, Rathman W, Dickhaus T, et al. Neuropathic pain in diabetes and normal glucose tolerance. The MONICA/KORA Augsburg Surveys S2 and S3. Pain Medicine 2009; 10 (2):393-400.
Hughes RA. A controlled investigation of the cause o chronical idiopathic axonal plyneuropathy. Brain 2004; 127; 1723-1730.
Obrosova IG, Ilnytska O, Lyzogubov VV, et al. High fat diet induced neuropathy of pre-diabetes and obesity. Effects of “healthy” diet and aldose reductase inhibition. Diabetes 2007; 56: 2598 - 2608.
Davinson EP, Coppey L, Calcut NA et al. Diet-induced obesity in Sprague-Dawlwy rats causes microcascular and neural dysfunction. Diabetes Metab. Res. Rew. 2010; 26: 306-318.
Obrosova IG, Linytska O, Lyzogubov W, et al. High fat diet induced neuropathy of pre-diabetes and obesity: effects of “healthy” diet and aldose reductase inhibition. Diabetes 2007; 56: 2598-2608.
Oltman CL, Coppey LJ, Gellett JS, et al. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am. J. Phisiol. Endocrinol. Metab. 2005; 289: E113-E122.
Vincent AM, Hinder LM, Pop-Busui R, et al. Hyperlipemia: a new therapeutic target for diabetic neuropathy. J. Peripher Nerv. Syst. 2009; 14: 257-267.
Oltman CL, Davinson EP, Coppey LJ, et al. Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes. Metab. 2009; 11: 223-233.
Pleiner J, Schaler G, Mittermayer F, et al. FFA-induced endothelial dysfunction can be corrected by vitamin C. J. Clin. Endocrinol. Metab. 2002; 87: 2913-2917.
Smith AG, Singleton JR. Idiopatic neuropathy, prediabetes and metabolic syndrome (Abstract). J. Neuro. Sci 2006; 242: 9-14.
- Testafaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005; 352: 341-50.
Vincent AM, Hayes JM, McLean LL, et al. Dyslipidemia-induced neuropathy in mice: the rol of oxLDL/LOX-1. Diabetes 2009; 58: 2376-85.
Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are high risk syndrome. J. Neurol. Sci. 2008; 273: 25-8.
Singleton JR, Smith AG, Russell JW, et al. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-73.
Callaghan B, Feldman E. The Metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann. Neurol. 2013; 74: 397-403.
Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60; 108-111.
Tavee J, Zhou L. Small fiber neurophaty: a burning problem. Cleveland Clinic Journal of Medicine 2009; 76: 5; 297-305.
Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat. Rev. Endocrinol. 2011; 7: 11; 682-690.
Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial hyperglucemia te main culprit? A mini-review. Gerontology 2013; 59: 193-198.
McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005; 4: 543-555.
Chain J, Herrmann DN, Staton M, et al. Pain ful samall- fiber neuropathy in Sjogren syndrome. Neurology 2005; 65: 925-927.
Brannagan TH, Hays AP, Chin SS, et al. Small-fiber neuropathy/neuropathy associated with celiac disease: skin biopsy findings. Arch. Neurol. 2005; 62: 1574-1578.
Gorson KC, Hermann DN, Thiagarajan R, et al. Nom-length dependent small fibre neuropathy/ganglionopathy. J. Neurol. Neurosurg. Psychiatric. 2008; 79:163-169.
The Diabetes Prevention Program (DPP) Research Group. Description of lifestyle intervention. Diabetes Care 2002 Dec.; 25(12): 2165-2171.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346:393-403.
Gordon Smith A, Russell J, Feldman EL, et al. Lifestyle intevention for pre-diabetic neuropathy. Diabetes Care 2006; 29: 6, 1294-1299.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
